These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 20056642

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X, Na R, Huang T, Wang L, Tao S, Tian L, Chen Z, Jiao Y, Kang J, Zheng S, Xu J, Sun J, Qi J.
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.
    Zhang A, Zhang J, Plymate S, Mostaghel EA.
    Horm Cancer; 2016 Apr; 7(2):104-13. PubMed ID: 26797685
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.
    Park JY, Tanner JP, Sellers TA, Huang Y, Stevens CK, Dossett N, Shankar RA, Zachariah B, Heysek R, Pow-Sang J.
    Urology; 2007 Aug; 70(2):374-9. PubMed ID: 17826523
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
    Onen IH, Ekmekci A, Eroglu M, Polat F, Biri H.
    DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
    Allen NE, Reichardt JK, Nguyen H, Key TJ.
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.
    Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM.
    Endocrinology; 2003 Jul; 144(7):2922-32. PubMed ID: 12810547
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correlation between circulatory, local prostatic, and intra-prostatic androgen levels.
    Olsson M, Ekström L, Guillemette C, Belanger A, Rane A, Gustafsson O.
    Prostate; 2011 Jun 15; 71(9):909-14. PubMed ID: 21541968
    [Abstract] [Full Text] [Related]

  • 19. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
    Scariano JK, Treat E, Alba F, Nelson H, Ness SA, Smith AY.
    Prostate; 2008 Dec 01; 68(16):1798-805. PubMed ID: 18780294
    [Abstract] [Full Text] [Related]

  • 20. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
    Allen NE, Forrest MS, Key TJ.
    Cancer Epidemiol Biomarkers Prev; 2001 Mar 01; 10(3):185-9. PubMed ID: 11303586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.